Browsing by Author "Rivas, María."
Now showing items 1-4 of 4
-
Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment
Rivas, María.; Berro, Mariano.; Kusminsky, Gustavo.; Et al. (Springer Nature, 2020-01)Abstract Allogeneic stem cell transplant (alloSCT) is a current treatment option for patients with refractory/relapsed classic Hodgkin lymphoma (CHL), including those who have failed an autologous transplantation. We ... -
Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
Berro, Mariano.; Arbeldibe, Jorge.; Rivas, María.; Basquiera, Ana.; Ferini, Gonzalo.; Vitriú, Adriana.; Foncuberta, Cecilia.; et al. (Elsevier, 2017-10-01)The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score is a useful tool to assess the risk for nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation. Although the ... -
Post-transplant cyclophosphamide demonstrates lower non-relapse mortality and better graft-versus-host disease/relapse-free survival compared with antithymocyte globulin in unrelated donor hematopoietic stem cell transplantation. A single-center experience
Berro, Mariano.; Rivas, María.; Trucco, José.; Et al. (Springer Nature, 2021-04)Post-transplant cyclophosphamide demonstrates lower non-relapse mortality and better graft-versus-host disease/relapse-free survival compared with antithymocyte globulin in unrelated donor hematopoietic stem cell ... -
Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score
Berro, Mariano.; Rivas, María.; Tisi Baña, Matías.; Et al. (Elsevier, 2020-10)Abstract There have been several efforts to predict mortality after autologous stem cell transplantation (ASCT), such as the hematopoietic cell transplant-comorbidity index (HCT-CI), described for allogeneic stem cell ...